A new updated “Oral Anti-Diabetic Therapy Guidelines for Type 2 Diabetes Mellitus” prescribing algorithm has been developed. This is very similar to the algorithm published in 2021. The main differences are: 1. Prescribing of SGLT-2 inhibitors is simplified with Dapagliflozin replacing Empagliflozin/Canagliflozin. 2. There is an increased focus on cardiorenal protection. In essence, for people
Year: 2023
Guidance from the Diabetes MCN Prescribing Subgroup on Tresiba insulin shortages
A Medicine Supply Alert Notice (MSAN) has been distributed for Tresiba (insulin degludec) FlexTouch 100units/ml solution for injection 3ml pre-filled pens (MSAN(2023)09.pdf). This is relevant from August 2023 to 2024. Tresiba Penfill® (insulin degludec) 100units/ml solution for injection 3ml cartridges remain available and can support increased demand. Patients will require an alternative insulin pen device for
